COMMUNIQUÉS West-GlobeNewswire

Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD
07/03/2024
CHARLESTOWN, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a non- [...]
LSL Pharma Group Announces a Combination of Private Placements for Maximum Aggregate Gross Proceeds of $8 Million
07/03/2024
Up to $3.5 M in cash proceeds Up to $4.5 M in debts conversion Proceeds to be used to further expand production capacity BOUCHERVILLE, Québec, March 07, 2024 (GLOBE NEWSWIRE) -- LSL PHARMA GROUP INC . (TSXV: LSL) (the [...]
Le groupe LSL Pharma annonce une combinaison de placements privés pour un produit brut total maximum de 8 millions $
07/03/2024
Jusqu’à 3,5 millions $ de produits en espèces Jusqu'à 4,5 millions $ en conversion de dettes Les produits du financement serviront à augmenter la capacité de production BOUCHERVILLE, Québec, 07 mars 2024 (GLOBE NEWSWIRE [...]
Malaysia Makes Historic Debut in World's Best Hospitals 2024 by Newsweek
07/03/2024
Solidifying Its Position as a Leading Medical Tourism Hub KUALA LUMPUR, Malaysia, March 07, 2024 (GLOBE NEWSWIRE) -- In a monumental achievement for the nation, two Malaysian hospitals have been recognised in the highly [...]
BioNTech Announces Planned Retirement of Sean Marett
07/03/2024
Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the [...]
Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US
07/03/2024
Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy against [...]
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
07/03/2024
OGAP ® -Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discovery OGAP-Verify is now more sensitive than Immunohistochemistry ( [...]
MitoRx Therapeutics Strengthens Scientific Advisory Board with Appointment of Four International Experts
07/03/2024
Company is advancing mitochondriotropic therapeutic pipeline for rare neuromuscular disorders and neurodegenerative diseases OXFORD, United Kingdom, March 07, 2024 (GLOBE NEWSWIRE) -- MitoRx Therapeutics (MitoRx), a [...]
Nexstim Plc: Invitation to the Annual General Meeting
07/03/2024
Company announcement, Helsinki, 7 March 2024 at 10 AM (EET) Nexstim Plc: Invitation to the Annual General Meeting Nexstim Plc (NXTMH:HEX) (“Nexstim” or the “Company”) is pleased to invite shareholders to the Annual [...]
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
07/03/2024
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held, clinical stage [...]
Highlights to be presented at Novo Nordisk’s Capital Markets Day 2024
07/03/2024
Bagsværd, Denmark, 7 March 2024 – Novo Nordisk is today hosting a Capital Markets Day (CMD) where the company is providing a progress update on its Strategic Aspirations 2025. The day will be centred around the [...]
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
07/03/2024
With the 18-month minimum follow-up of the patients in the INITIUM trial, the trial did not meet the primary endpoint of prolonging progression-free survival (PFS). Median PFS was not reached in either arm. Evaluation [...]
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
07/03/2024
TUSTIN, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO), announced today the pricing of $160 million [...]
La spécialiste en oncologie Jill DeSimone rejoint le Conseil d’administration d’iTeos
07/03/2024
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 07 mars 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le [...]
Patricia Allen rejoint le Conseil d’administration de Zenas BioPharma
07/03/2024
WALTHAM, Massachusetts, 07 mars 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à rejoindre les leaders du développement et de la commercialisation de thérapies [...]
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/03/2024
LOWELL, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate [...]
PickleJar Confirms Completion of Its Two-Year Audit and Applies for FINRA Name Change
06/03/2024
Company furthers its corporate mission, aiming to expand brand reach and shareholder communications HOUSTON, TX, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – PickleJar Entertainment Group (OTC:NREG f/k/a [...]
Viemed Healthcare Announces Record 2023 Financial Results
06/03/2024
LAFAYETTE, La., March 06, 2024 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national leader in respiratory care and technology-enabled home medical equipment services, [...]
BioVie Inc. Announces Closing of Public Offering
06/03/2024
CARSON CITY, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions [...]

Pages